RxDoctor Payments Data

Lisa Matiaco, PA

Physician Assistant · Republic, WANPI 1154500536

Payments from drug & device makers

$462in general payments, 2019–2025

Across 24 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$151
  • Johnson & Johnson$70
  • AbbVie$67
  • Novo Nordisk$37
  • Amgen$35
  • GSK$35
  • plus $68 from 3 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis8$151
Johnson & Johnson3$70
AbbVie3$67
Novo Nordisk2$37
Amgen2$35
GSK2$35
AstraZeneca2$32
Lilly USA, LLC1$21
Bayer1$15

How this compares

$462 in reported general payments places this provider in the 75th percentile of 2,741 physician assistant providers in Washington.

See all physician assistant providers in Washington

Medicare billing

Part B allowed, 2024
$38,783
Medicare patients
100
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin28$42,723
GastrocromCromolyn Sodium13$40,427
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,979
OzempicSemaglutide20$24,259
XareltoRivaroxaban21$22,634
TrulicityDulaglutide12$17,972
EliquisApixaban19$13,671
SymbicortBudesonide/Formoterol Fumarate11$3,569
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,132
Albuterol Sulfate HfaAlbuterol Sulfate54$2,016
Atorvastatin Calcium144$1,856
Amlodipine Besylate204$1,517
Levothyroxine Sodium135$1,445
Metoprolol Succinate88$1,418
Gabapentin117$1,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$35$26,97940 claims
Novo NordiskOzempic$37$24,25920 claims
Johnson & JohnsonXarelto$70$22,63421 claims
Lilly USA, LLCTrulicity$21$17,97212 claims
AstraZenecaSymbicort$32$3,56911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,741 physician assistant providers in Washington.

Other physician assistant in Republic

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →